Bio Impact Capital LLC Inozyme Pharma, Inc. Transaction History

Bio Impact Capital LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$2.71 - $4.5 $8,422 - $13,986	-3,108 Reduced 0.95%	323,813 $1.38 Million
Q2 2023 Aug 14, 2023	BUY	$4.93 - $6.74 $459,441 - $628,120	93,193 Added 39.87%	326,921 $1.82 Million
Q1 2023 May 12, 2023	BUY	$1.3 - $5.73 $4,196 - $18,496	3,228 Added 1.4%	233,728 $1.34 Million
Q4 2022 Feb 14, 2023	SELL	$1.05 - $2.82 $452,176 - $1.21 Million	-430,644 Reduced 65.14%	230,500 $242,000
Q3 2022 Nov 14, 2022	SELL	$2.57 - $5.45 $9,858 - $20,906	-3,836 Reduced 0.58%	661,144 $1.77 Million
Q2 2022 Aug 11, 2022	BUY	$3.2 - $5.96 $1.18 Million - $2.21 Million	370,000 Added 125.43%	664,980 $3.17 Million
Q1 2022 May 13, 2022	SELL	$3.87 - $7.55 $29,547 - $57,644	-7,635 Reduced 2.52%	294,980 $1.21 Million
Q4 2021 Feb 11, 2022	SELL	$5.58 - $11.5 $101,048 - $208,253	-18,109 Reduced 5.65%	302,615 $2.06 Million
Q3 2021 Nov 15, 2021	BUY	$11.12 - $19.4 $3.57 Million - $6.22 Million	320,724 New	320,724 $3.72 Million

53.2M

3.7K

5.8K

Ticker INZY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,145,700
Market Cap $57M
Description
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...

Get notified when there are updates to the investment portfolio of Bio Impact Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Bio Impact Capital LLC with notifications on news.